应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ZLAB 再鼎医药
休市中 08-23 16:00:00 EDT
18.02
+0.47
+2.68%
盘后
18.02
+0.00
0.00%
19:56 EDT
最高
18.19
最低
17.50
成交量
30.77万
今开
17.81
昨收
17.55
日振幅
3.93%
总市值
17.68亿
流通市值
15.93亿
总股本
9,814万
成交额
552.62万
换手率
0.35%
流通股本
8,842万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
再鼎医药(09688)上涨5.04%,报13.76元/股
金融界 · 08-22 15:48
再鼎医药(09688)上涨5.04%,报13.76元/股
再鼎医药早盘涨近3% 二季度收入同比增长45%
新浪港股 · 08-22 11:14
再鼎医药早盘涨近3% 二季度收入同比增长45%
港股异动 | 再鼎医药(09688)涨近3% 二季度收入同比增超四成 艾加莫德销售增长势头强劲
智通财经 · 08-22 10:43
港股异动 | 再鼎医药(09688)涨近3% 二季度收入同比增超四成 艾加莫德销售增长势头强劲
再鼎医药上涨2.17%,报17.46美元/股
金融界 · 08-21
再鼎医药上涨2.17%,报17.46美元/股
南向资金8月20日净卖出再鼎医药22.72万股 连续3日减持
自选股智能写手 · 08-21
南向资金8月20日净卖出再鼎医药22.72万股 连续3日减持
再鼎医药上涨2.04%,报16.99美元/股
金融界 · 08-17
再鼎医药上涨2.04%,报16.99美元/股
【券商聚焦】中信建投维持再鼎医药(09688)“买入”评级 指二季度收入高增 艾加莫德表现超预期
金吾财讯 · 08-15
【券商聚焦】中信建投维持再鼎医药(09688)“买入”评级 指二季度收入高增 艾加莫德表现超预期
南向资金8月14日净买入再鼎医药77.46万股 连续3日增持
自选股智能写手 · 08-15
南向资金8月14日净买入再鼎医药77.46万股 连续3日增持
【券商聚焦】海通国际维持再鼎医药(09688)优于大市评级 指其上半年销售表现良好 上调全年指引
金吾财讯 · 08-14
【券商聚焦】海通国际维持再鼎医药(09688)优于大市评级 指其上半年销售表现良好 上调全年指引
海通国际:维持再鼎医药(09688)“优于大市”评级 目标价下调至65.76港元
智通财经网 · 08-14
海通国际:维持再鼎医药(09688)“优于大市”评级 目标价下调至65.76港元
再鼎医药(09688)根据2024年股权激励计划授出涉及合共7000股美国存托股份的受限制股份单位
智通财经 · 08-13
再鼎医药(09688)根据2024年股权激励计划授出涉及合共7000股美国存托股份的受限制股份单位
再鼎医药8月12日获南向资金加仓669.45万股
自选股智能写手 · 08-13
再鼎医药8月12日获南向资金加仓669.45万股
再鼎医药上涨2.09%,报16.6美元/股
金融界 · 08-12
再鼎医药上涨2.09%,报16.6美元/股
再鼎医药2024财年第二财季实现净利润-80.28百万美元,同比增加33.65%
自选股智能写手 · 08-12
再鼎医药2024财年第二财季实现净利润-80.28百万美元,同比增加33.65%
异动解读 | 再鼎医药股价大跌7.04% 市场对公司前景存疑
异动解读 · 08-11
异动解读 | 再鼎医药股价大跌7.04% 市场对公司前景存疑
再鼎医药下跌5.33%,报16.33美元/股
金融界 · 08-09
再鼎医药下跌5.33%,报16.33美元/股
再鼎医药盘中异动 早盘股价大跌5.01%报16.39美元
自选股智能写手 · 08-09
再鼎医药盘中异动 早盘股价大跌5.01%报16.39美元
大行评级|美银:上调再鼎医药目标价至19.38港元 维持“买入”评级
格隆汇 · 08-09
大行评级|美银:上调再鼎医药目标价至19.38港元 维持“买入”评级
再鼎医药盘中异动 早盘急速拉升5.17%
自选股智能写手 · 08-08
再鼎医药盘中异动 早盘急速拉升5.17%
再鼎医药:上半年亏损1.337亿美元,同比收窄21%
和讯网 · 08-08
再鼎医药:上半年亏损1.337亿美元,同比收窄21%
公司概况
公司名称:
再鼎医药
所属市场:
NASDAQ
上市日期:
--
主营业务:
Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。
发行价格:
--
{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":18.02,"timestamp":1724443200000,"preClose":17.55,"halted":0,"volume":307659,"hourTrading":{"tag":"盘后","latestPrice":18.02,"preClose":18.02,"latestTime":"19:56 EDT","volume":117676,"amount":2120522.6064,"timestamp":1724457400295},"delay":0,"floatShares":88421312,"shares":98139814,"eps":-3.068928,"marketStatus":"休市中","marketStatusCode":7,"change":0.47,"latestTime":"08-23 16:00:00 EDT","open":17.81,"high":18.19,"low":17.5,"amount":5526162.035889,"amplitude":0.039316,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.068928,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1724659200000},"adr":1,"listingDate":1505880000000,"adjPreClose":17.55,"adrRate":10,"preHourTrading":{"tag":"盘前","latestPrice":17.8,"preClose":17.55,"latestTime":"09:29 EDT","volume":4,"amount":70.94,"timestamp":1724419770008},"postHourTrading":{"tag":"盘后","latestPrice":18.02,"preClose":18.02,"latestTime":"19:56 EDT","volume":117676,"amount":2120522.6064,"timestamp":1724457400295},"volumeRatio":0.6304366267579554,"impliedVol":0.2795,"impliedVolPercentile":0.0437},"requestUrl":"/m/hq/s/ZLAB/wiki","defaultTab":"wiki","newsList":[{"id":"2461366478","title":"再鼎医药(09688)上涨5.04%,报13.76元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461366478","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461366478?lang=zh_cn&edition=full","pubTime":"2024-08-22 15:48","pubTimestamp":1724312925,"startTime":"0","endTime":"0","summary":"8月22日,再鼎医药(09688)盘中上涨5.04%,截至15:48,报13.76元/股,成交3771.67万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物,以满足全球患者的医疗需求。关键经营数据方面,公司以其强大的研发能力和全球化运营策略,致力于成为全球领先的生物制药公司。截至2024年中报,再鼎医药营业总收入13.37亿元、净利润-9.53亿元。8月27日,再鼎医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/22154842601301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZLAB","09688","BK4526","BK4585","BK4588","BK1161","BK1574","BK4139","BK4531","BK4548","BK1588"],"gpt_icon":0},{"id":"2461331432","title":"再鼎医药早盘涨近3% 二季度收入同比增长45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461331432","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461331432?lang=zh_cn&edition=full","pubTime":"2024-08-22 11:14","pubTimestamp":1724296440,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 再鼎医药(09688)早盘上涨2.60%,现报13.44港元,成交额1704.20万港元。\n 中信建投证券发布研报指出,再鼎医药公布2024年第二季度业绩,24Q2产品收入为1.001亿美元,同比增长45%。亏损净额为8,030万美元,亏损同比收窄33.6%。该行表示,公司目前已经上市的五款产品均实现销售收入,其中艾加莫德增长势头强劲,全年销售指引上调至超过8,000万美元。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-22/doc-inckntrq0574788.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-22/doc-inckntrq0574788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","ZLAB","BK4588","BK4526","09688","BK4548","BK1588","BK4585","BK1574","BK1161","BK4531"],"gpt_icon":0},{"id":"2461081336","title":"港股异动 | 再鼎医药(09688)涨近3% 二季度收入同比增超四成 艾加莫德销售增长势头强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2461081336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461081336?lang=zh_cn&edition=full","pubTime":"2024-08-22 10:43","pubTimestamp":1724294634,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,再鼎医药(09688)涨近3%,截至发稿,涨2.75%,报13.46港元,成交额1395.53万港元。中信建投证券发布研报指出,再鼎医药公布2024年第二季度业绩,24Q2产品收入为1.001亿美元,同比增长45%。亏损净额为8,030万美元,亏损同比收窄33.6%。该行表示,公司目前已经上市的五款产品均实现销售收入,其中艾加莫德增长势头强劲,全年销售指引上调至超过8,000万美元。该行认为,随着未来两到三年内公司多个新产品和新适应证获批,营收将会快速增长,并且通过收入增长、充足的现金储备、持续关注效率和生产力提升,有望在2025年底前实现公司盈利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","BK4526","BK1588","BK4588","BK4585","BK4139","BK4531","BK1574","BK4548","ZLAB","BK1161"],"gpt_icon":0},{"id":"2461878180","title":"再鼎医药上涨2.17%,报17.46美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461878180","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461878180?lang=zh_cn&edition=full","pubTime":"2024-08-21 23:28","pubTimestamp":1724254109,"startTime":"0","endTime":"0","summary":"8月21日,再鼎医药(ZLAB)盘中上涨2.17%,截至23:28,报17.46美元/股,成交748.66万美元。财务数据显示,截至2024年06月30日,再鼎医药收入总额1.88亿美元,同比增长42.53%;归母净利润-1.34亿美元,同比增长21.34%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/08/21232842583894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["ZLAB","BK1161","BK4526","09688","BK1574","BK4531","BK4588","BK4548","BK4139","BK4585","BK1588"],"gpt_icon":0},{"id":"2461863336","title":"南向资金8月20日净卖出再鼎医药22.72万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2461863336","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461863336?lang=zh_cn&edition=full","pubTime":"2024-08-21 09:30","pubTimestamp":1724203817,"startTime":"0","endTime":"0","summary":"8月20日,南向资金减持再鼎医药22.72万股连续3日减持。截止当日收盘,港股通共持有再鼎医药10334.94万股,占流通股10.37%。港股通减持金额前五个股分别为美团-W、药明生物、中国中药、建设银行、理想汽车-W。再鼎医药近5个交易日上涨3.68%,港股通累计减持3.30万股;近20个交易日下跌13.37%,港股通累计增持627.12万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408210933129f3fe13a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408210933129f3fe13a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1574","ZLAB","BK1161","09688"],"gpt_icon":0},{"id":"2460242135","title":"再鼎医药上涨2.04%,报16.99美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2460242135","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460242135?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:56","pubTimestamp":1723827367,"startTime":"0","endTime":"0","summary":"8月17日,再鼎医药(ZLAB)盘中上涨2.04%,截至00:56,报16.99美元/股,成交167.34万美元。财务数据显示,截至2024年06月30日,再鼎医药收入总额1.88亿美元,同比增长42.53%;归母净利润-1.34亿美元,同比增长21.34%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/08/17005642449912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4588","BK4585","BK4531","BK1574","BK4548","BK1161","ZLAB","09688","BK4526","BK1588","BK4139"],"gpt_icon":0},{"id":"2459941112","title":"【券商聚焦】中信建投维持再鼎医药(09688)“买入”评级 指二季度收入高增 艾加莫德表现超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2459941112","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459941112?lang=zh_cn&edition=full","pubTime":"2024-08-15 15:55","pubTimestamp":1723708558,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研指,再鼎医药 公布2024年第二季度业绩,24Q2产品收入为1.001亿美元,同比增长45%。亏损净额为8,030万美元,亏损同比收窄33.6%。该行表示,公司目前已经上市的五款产品均实现销售收入,其中艾加莫德增长势头强劲,全年销售指引上调至超过8,000万美元。该行预计2024-2026年,公司实现营业收入分别为25.93亿元、38.71亿元、57.83亿元。考虑到公司License-in模式日渐成熟,内部研发和全球化布局深化,维持“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTI0OTYzODIzODM=.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942374","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2459450409","title":"南向资金8月14日净买入再鼎医药77.46万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2459450409","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459450409?lang=zh_cn&edition=full","pubTime":"2024-08-15 09:31","pubTimestamp":1723685495,"startTime":"0","endTime":"0","summary":"8月14日, 南向资金增持再鼎医药77.46万股,连续3日增持。截止当日收盘,港股通共持有再鼎医药10415.70万股,占流通股10.44%。再鼎医药近5个交易日下跌19.36%,港股通累计增持673.74万股;近20个交易日下跌11.90%,港股通累计增持429.91万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150942149599ca36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408150942149599ca36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4548","BK4588","BK4585","BK4139","ZLAB","09688","BK4531"],"gpt_icon":0},{"id":"2459254193","title":"【券商聚焦】海通国际维持再鼎医药(09688)优于大市评级 指其上半年销售表现良好 上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2459254193","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459254193?lang=zh_cn&edition=full","pubTime":"2024-08-14 10:58","pubTimestamp":1723604339,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际发研指,再鼎医药 2024Q2产品收入净额1.0亿美元,其中艾加莫德2320万美元;毛利率64.9%;R&D费用6163万美元,R&D费用占产品收入61.6%;SG&A费用7971万美元,SG&A费用占产品收入79.6%。净亏损8028万美元,去年同期为1.2亿美元。截至2024年6月30日,公司在手现金、现金等价物、受限制现金7.3亿美元。艾加莫德销售超预期,全年指引上调至8000万美元。该行指出,2024Q2,艾加莫德销售2320万美元,环比2024Q1增长76%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200915/MGYzMDMzNGFiY2IxZDI0MzU2YTQ4NTEzZTUyODAwMDc0ODA2MTY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/MGYzMDMzNGFiY2IxZDI0MzU2YTQ4NTEzZTUyODAwMDc0ODA2MTY2.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942248","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2459603671","title":"海通国际:维持再鼎医药(09688)“优于大市”评级 目标价下调至65.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459603671","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459603671?lang=zh_cn&edition=full","pubTime":"2024-08-14 09:30","pubTimestamp":1723599015,"startTime":"0","endTime":"0","summary":"海通认为在艾加莫德以及上市3款潜在重磅产品的销售拉动下,公司2023-2028年有望实现CAGR~50%的收入增长。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240814/20240814093845_38498.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240814/20240814093845_38498.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2459240689","title":"再鼎医药(09688)根据2024年股权激励计划授出涉及合共7000股美国存托股份的受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2459240689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459240689?lang=zh_cn&edition=full","pubTime":"2024-08-13 17:31","pubTimestamp":1723541483,"startTime":"0","endTime":"0","summary":"智通财经APP讯,再鼎医药(09688)发布公告,于2024年8月12日(美国东部时间),公司根据2024年股权激励计划向7名承授人授出涉及合共7000股美国存托股份的受限制股份单位。股份于授出日期的收市价为每股美国存托股份16.27美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1163539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","BK4585","ZLAB","09688","BK4531","BK4588","BK4139","BK1161","BK1588","BK1574","BK4526"],"gpt_icon":0},{"id":"2459999404","title":"再鼎医药8月12日获南向资金加仓669.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459999404","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459999404?lang=zh_cn&edition=full","pubTime":"2024-08-13 09:31","pubTimestamp":1723512687,"startTime":"0","endTime":"0","summary":"8月12日, 南向资金增持再鼎医药669.45万股。截止当日收盘,港股通共持有再鼎医药10319.05万股,占流通股10.35%。再鼎医药近5个交易日下跌9.87%,港股通累计增持628.87万股;近20个交易日下跌9.61%,港股通累计增持244.47万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408130942289f25cf48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408130942289f25cf48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4526","BK4139","BK4531","BK4548","BK4588","09688","ZLAB"],"gpt_icon":0},{"id":"2458875279","title":"再鼎医药上涨2.09%,报16.6美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2458875279","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458875279?lang=zh_cn&edition=full","pubTime":"2024-08-12 23:03","pubTimestamp":1723475023,"startTime":"0","endTime":"0","summary":"8月12日,再鼎医药(ZLAB)盘中上涨2.09%,截至23:03,报16.6美元/股,成交165.06万美元。财务数据显示,截至2024年06月30日,再鼎医药收入总额1.88亿美元,同比增长42.53%;归母净利润-1.34亿美元,同比增长21.34%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/08/12230342282874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4526","BK4531","BK4139","BK4585","BK1574","BK1161","BK4588","BK1588","ZLAB","BK4548","09688"],"gpt_icon":0},{"id":"2458924406","title":"再鼎医药2024财年第二财季实现净利润-80.28百万美元,同比增加33.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458924406","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458924406?lang=zh_cn&edition=full","pubTime":"2024-08-12 00:19","pubTimestamp":1723393162,"startTime":"0","endTime":"0","summary":"8月12日,再鼎医药公布财报,公告显示公司2024财年第二财季净利润为-80.28百万美元,同比增加33.65%;其中营业收入为1.01亿美元,同比增加46.67%,每股基本收益为-0.82美元。从资产负债表来看,再鼎医药总负债2.83亿美元,其中短期债务77.88百万美元,资产负债比为3.49,流动比率为3.46。机构评级:截至2024年8月12日,当前有12家机构对再鼎医药目标价做出预测,其中目标均价为50.63美元,其中最低目标价为19.23美元,最高目标价为86.38美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120019349f222be2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408120019349f222be2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB"],"gpt_icon":0},{"id":"1128545244","title":"异动解读 | 再鼎医药股价大跌7.04% 市场对公司前景存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=1128545244","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128545244?lang=zh_cn&edition=full","pubTime":"2024-08-11 23:52","pubTimestamp":1723391553,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中股价大跌7.04%,引发市场广泛关注。分析人士认为,这主要源于以下几个原因:. 首先,尽管美银证券上调了再鼎医药的目标价至19.38港元,并维持\"买入\"评级,但市场对公司未来前景仍存在一定担忧。再鼎医药出现大手成交,成交价较上日收市价下跌1.82%,反映了投资者的看空情绪。这令市场对公司的盈利能力产生质疑,加剧了对公司前景的担忧。分析人士指出,这可能反映了投资者存在获利了结需求,导致股价下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB"],"gpt_icon":0},{"id":"2458551829","title":"再鼎医药下跌5.33%,报16.33美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2458551829","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458551829?lang=zh_cn&edition=full","pubTime":"2024-08-09 23:41","pubTimestamp":1723218078,"startTime":"0","endTime":"0","summary":"8月9日,再鼎医药(ZLAB)盘中下跌5.33%,截至23:41,报16.33美元/股,成交391.93万美元。财务数据显示,截至2024年06月30日,再鼎医药收入总额1.88亿美元,同比增长42.53%;归母净利润-1.34亿美元,同比增长21.34%。大事提醒:8月6日,再鼎医药2024财年中报归属股东应占溢利-1.337亿美元,同比增长21.34%,基本每股收益-0.14美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/08/09234142232735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4526","BK4531","BK4139","BK4585","BK1574","BK1161","BK4588","BK1588","ZLAB","BK4548","09688"],"gpt_icon":0},{"id":"2458559985","title":"再鼎医药盘中异动 早盘股价大跌5.01%报16.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458559985","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458559985?lang=zh_cn&edition=full","pubTime":"2024-08-09 21:31","pubTimestamp":1723210294,"startTime":"0","endTime":"0","summary":"截至发稿,该股报16.39美元/股,成交量6404股,换手率0.01%,振幅2.38%。机构评级方面,在所有13家参与评级的机构中,92%的券商给予买入建议,8%的券商给予持有建议,无券商给予卖出建议。再鼎医药股票所在的生物技术行业中,整体涨幅为0.32%。消息层面,截至21时31分,再鼎医药股票正面舆情新闻比例22.86%。《大行评级|美银:上调再鼎医药目标价至19.38港元 维持“买入”评级》资讯为影响再鼎医药的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213134aefe259c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809213134aefe259c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","BK4526","BK4531","BK4588","BK4548","BK4139","BK4585"],"gpt_icon":0},{"id":"2458534844","title":"大行评级|美银:上调再鼎医药目标价至19.38港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2458534844","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458534844?lang=zh_cn&edition=full","pubTime":"2024-08-09 15:11","pubTimestamp":1723187476,"startTime":"0","endTime":"0","summary":"格隆汇8月9日|美银证券发表报告指,再鼎医药次季商业化表现稳健,由于销售表现稳健,且研发进度如期推进,目标价由16.28港元升至19.38港元,维持“买入”评级。报告指,考虑到旗下药物VYVGART/NUZYRA/QINLOCK在纳入国家医保药品目录后的强劲增长,调高2024年以后的营收预测。此外,基于公司管线进展,相应更新POS和营收预测。由于营收组合改变,下调短期毛利率预测。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408091511249f1cbfbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408091511249f1cbfbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2457319594","title":"再鼎医药盘中异动 早盘急速拉升5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457319594","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457319594?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:41","pubTimestamp":1723124475,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时41分,再鼎医药股票出现波动,股价快速上涨5.17%。截至发稿,该股报17.51美元/股,成交量1.9274万股,换手率0.02%,振幅2.94%。再鼎医药股票所在的生物技术行业中,整体涨幅为0.93%。消息层面,截至21时41分,再鼎医药股票正面舆情新闻比例24.24%。《再鼎医药:上半年亏损1.337亿美元,同比收窄21%》资讯为影响再鼎医药的重要信息。该信息摘要如下:再鼎医药在港股市场遭遇重挫,股价跌幅超过14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808214116a1d42795&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808214116a1d42795&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4588","BK4585","BK4139","BK4531","BK4548","ZLAB"],"gpt_icon":0},{"id":"2457833365","title":"再鼎医药:上半年亏损1.337亿美元,同比收窄21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457833365","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457833365?lang=zh_cn&edition=full","pubTime":"2024-08-08 10:15","pubTimestamp":1723083345,"startTime":"0","endTime":"0","summary":"快讯正文【港股再鼎医药股价大跌超14%,上半年亏损1.337亿美元】再鼎医药在港股市场遭遇重挫,股价跌幅超过14%。公司最新财报显示,上半年累计亏损1.337亿美元,尽管亏损额较去年同期有所收窄,但市场反应依然强烈。亏损同比减少21%,显示出公司在成本控制和运营效率上有所提升,但投资者对未来盈利预期仍持谨慎态度。下载和讯APP查看快讯,体验更佳>>","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080811053695876fe7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080811053695876fe7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4585","ZLAB","BK4531","BK4588","BK4139","BK4526"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.055},{"period":"1month","weight":-0.0556},{"period":"3month","weight":0.0056},{"period":"6month","weight":-0.0963},{"period":"1year","weight":-0.2554},{"period":"ytd","weight":-0.3407}],"compareEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.0386},{"period":"3month","weight":0.0617},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2867},{"period":"ytd","weight":0.1827}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.113311},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.022208},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.101183},{"month":4,"riseRate":0.428571,"avgChangeRate":0.026877},{"month":5,"riseRate":0.571429,"avgChangeRate":0.03934},{"month":6,"riseRate":0.428571,"avgChangeRate":0.063316},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.00593},{"month":8,"riseRate":0.571429,"avgChangeRate":0.004093},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.113197},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.064295},{"month":11,"riseRate":0.714286,"avgChangeRate":0.168146},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.005362}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}